Nutcracker Therapeutics

About:

Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.

Website: https://www.nutcrackerx.com

Top Investors: ARCH Venture Partners, Bluebird Ventures

Description:

Nutcracker Therapeutics is a biotech company that develops and produces mRNA therapeutics on its proprietary, microfluidic, and biochip-based platform. The company specializes in a fully-integrated system for the production of mRNA-therapeutics at the push of a button that enables scalable on-demand experimental and manufacturing capacity, thereby enabling healthcare companies to produce complex multimodal therapeutics at point of care. Nutcracker Therapeutics combines the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. Its ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. Igor Khandros and Benjamin Eldridge established the company in Emeryville, California in 2018.

Total Funding Amount:

$241M

Headquarters Location:

Emeryville, California, United States

Founded Date:

2018-01-01

Contact Email:

info(AT)nutcrackerx.com

Founders:

Benjamin Eldridge, Igor Khandros

Number of Employees:

101-250

Last Funding Date:

2022-03-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai